Cipher Pharmaceuticals Debt
| CPH Stock | CAD 14.86 0.30 2.06% |
Cipher Pharmaceuticals has over 353,000 in debt which may indicate that it relies heavily on debt financing. At this time, Cipher Pharmaceuticals' Cash Flow To Debt Ratio is very stable compared to the past year. With a high degree of financial leverage come high-interest payments, which usually reduce Cipher Pharmaceuticals' Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
Cipher Pharmaceuticals' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Cipher Pharmaceuticals' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Cipher Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Cipher Pharmaceuticals' stakeholders.
For most companies, including Cipher Pharmaceuticals, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Cipher Pharmaceuticals, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Cipher Pharmaceuticals' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 2.697 | Book Value 3.863 | Operating Margin 0.1803 | Profit Margin 0.5992 | Return On Assets 0.0506 |
Cipher |
Cipher Pharmaceuticals Debt to Cash Allocation
Cipher Pharmaceuticals has accumulated 353 K in total debt with debt to equity ratio (D/E) of 62.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Cipher Pharmaceuticals has a current ratio of 1.04, suggesting that it is in a questionable position to pay out its financial obligations in time and when they become due. Debt can assist Cipher Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Cipher Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cipher Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cipher to invest in growth at high rates of return. When we think about Cipher Pharmaceuticals' use of debt, we should always consider it together with cash and equity.Cipher Pharmaceuticals Total Assets Over Time
Cipher Pharmaceuticals Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Cipher Pharmaceuticals uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Cipher Pharmaceuticals Debt Ratio | 16.0 |
Cipher Pharmaceuticals Corporate Bonds Issued
Cipher Short Long Term Debt Total
Short Long Term Debt Total |
|
Understaning Cipher Pharmaceuticals Use of Financial Leverage
Leverage ratios show Cipher Pharmaceuticals' total debt position, including all outstanding obligations. In simple terms, high financial leverage means that the cost of production, along with the day-to-day running of the business, is high. Conversely, lower financial leverage implies lower fixed cost investment in the business, which is generally considered a good sign by investors. The degree of Cipher Pharmaceuticals' financial leverage can be measured in several ways, including ratios such as the debt-to-equity ratio (total debt / total equity), or the debt ratio (total debt / total assets).
| Last Reported | Projected for Next Year | ||
| Short and Long Term Debt Total | 353 K | 335.4 K | |
| Net Debt | -39.5 M | -37.5 M | |
| Short Term Debt | 94 K | 89.3 K | |
| Long Term Debt Total | 294.3 K | 279.6 K | |
| Short and Long Term Debt | 6.9 M | 6.5 M | |
| Net Debt To EBITDA | (3.51) | (3.33) | |
| Debt To Equity | 0.24 | 0.45 | |
| Debt To Assets | 0.15 | 0.16 | |
| Long Term Debt To Capitalization | 0.32 | 0.46 | |
| Total Debt To Capitalization | 0.19 | 0.22 | |
| Debt Equity Ratio | 0.24 | 0.45 | |
| Debt Ratio | 0.15 | 0.16 | |
| Cash Flow To Debt Ratio | 1.05 | 1.10 |
Pair Trading with Cipher Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cipher Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cipher Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Cipher Stock
| 0.77 | AMZN | Amazon CDR | PairCorr |
| 0.64 | BNS | Bank of Nova Scotia | PairCorr |
| 0.64 | BMO | Bank of Montreal | PairCorr |
| 0.42 | RY | Royal Bank | PairCorr |
| 0.4 | TD-PFI | Toronto Dominion Bank | PairCorr |
The ability to find closely correlated positions to Cipher Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cipher Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cipher Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cipher Pharmaceuticals to buy it.
The correlation of Cipher Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cipher Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cipher Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cipher Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Cipher Stock
Cipher Pharmaceuticals financial ratios help investors to determine whether Cipher Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cipher with respect to the benefits of owning Cipher Pharmaceuticals security.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.